- Home
- ST vs MRUS Comparison
ST vs MRUS Comparison
Compare ST & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ST
- MRUS
- Stock Information
- Founded
- ST 1916
- MRUS 2003
- Country
- ST United States
- MRUS Netherlands
- Employees
- ST N/A
- MRUS N/A
- Industry
- ST Industrial Machinery/Components
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- ST Industrials
- MRUS Health Care
- Exchange
- ST Nasdaq
- MRUS Nasdaq
- Market Cap
- ST 3.1B
- MRUS 2.7B
- IPO Year
- ST 2010
- MRUS 2016
- Fundamental
- Price
- ST $26.07
- MRUS $56.07
- Analyst Decision
- ST Buy
- MRUS Strong Buy
- Analyst Count
- ST 13
- MRUS 15
- Target Price
- ST $34.08
- MRUS $88.87
- AVG Volume (30 Days)
- ST 1.8M
- MRUS 1.6M
- Earning Date
- ST 05-08-2025
- MRUS 05-07-2025
- Dividend Yield
- ST 1.84%
- MRUS N/A
- EPS Growth
- ST N/A
- MRUS N/A
- EPS
- ST 0.82
- MRUS N/A
- Revenue
- ST $3,837,310,000.00
- MRUS $54,732,000.00
- Revenue This Year
- ST N/A
- MRUS $39.00
- Revenue Next Year
- ST $4.31
- MRUS $7.48
- P/E Ratio
- ST $31.93
- MRUS N/A
- Revenue Growth
- ST N/A
- MRUS 42.77
- 52 Week Low
- ST $17.32
- MRUS $33.19
- 52 Week High
- ST $42.33
- MRUS $61.28
- Technical
- Relative Strength Index (RSI)
- ST 56.72
- MRUS 66.86
- Support Level
- ST $24.69
- MRUS $49.46
- Resistance Level
- ST $27.40
- MRUS $56.74
- Average True Range (ATR)
- ST 0.78
- MRUS 3.37
- MACD
- ST -0.04
- MRUS 1.57
- Stochastic Oscillator
- ST 33.87
- MRUS 91.31
About ST Sensata Technologies Holding plc
Sensata Technologies is a global supplier of sensors for transportation and industrial applications. Sensata sells a bevy of pressure, temperature, force, and position sensors into the automotive, heavy vehicle, industrial, heating, ventilation, and cooling, and aerospace markets. The majority of the firm's revenue comes from the automotive market, where it focuses on bumper-in applications.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.